Cephalon To Co-Market Vivitrex With Alkermes Through $500 Mil. Deal
This article was originally published in The Pink Sheet Daily
The alcohol dependence therapy, which could be approved in September, will initially target patients already on pharmaceutical treatment. Cephalon will pay Alkermes $160 mil. upfront and could pay an additional $110 mil. if the agent is approved, on top of other milestone payments and profit sharing arrangements.
You may also be interested in...
Alkermes/Cephalon expect to launch the renamed once-monthly naltrexone injection in the second quarter.
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications